Dr. Stephen L. Lee, M.D.,PH.D.
Neurology (Neurology Physician)
1 Medical Center Dr, Dhmc, Department Of Medicine Section Of Neurology
Lebanon, NH 03756
- Medicare participating
At a glance
- Medical school
- Washington University School of Medicine (1997)
- Years since graduation
- 29
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 307
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1997Medical school: Washington University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
NH license 12562 -
Neurocritical Care Physician
NH license 12562
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Mary Hitchcock Memorial Hospital Lebanon, NH
- Central Vermont Medical Center Barre, VT
- Cheshire Medical Center Keene, NH
- Alice Peck Day Memorial Hospital Lebanon, NH
- Mt Ascutney Hospital Windsor, VT
Medical groups
- Dartmouth-Hitchcock Clinic (1,472 clinicians)
- Mary Hitchcock Memorial Hospital (1,280 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 307
- Services billed
- 734
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 278 | 252 |
| Established patient office or other outpatient visit, 30-39 minutes | 183 | 164 |
| New patient office or other outpatient visit, 45-59 minutes | 52 | 52 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 39 | 18 |
| Injection of chemical for paralysis of nerve muscles on arm or leg, 1-4 muscles, first extremity | 20 | 12 |
| Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | 18 | 11 |
| Needle measurement of electrical activity in muscle with injection of chemical for paralysis of nerve muscle | 16 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Carbidopa-Levodopa (carbidopa/levodopa) Other prescribers in Lebanon, NH | 597 |
| Rytary (carbidopa/levodopa) Other prescribers in Lebanon, NH | 264 |
| Carbidopa-Levodopa Er (carbidopa/levodopa) Other prescribers in Lebanon, NH | 218 |
| Gabapentin Other prescribers in Lebanon, NH | 143 |
| Donepezil Hcl Other prescribers in Lebanon, NH | 123 |
| Clonazepam Other prescribers in Lebanon, NH | 107 |
| Primidone Other prescribers in Lebanon, NH | 100 |
| Entacapone | 83 |
| Sertraline Hcl Other prescribers in Lebanon, NH | 74 |
| Amantadine (amantadine hcl) Other prescribers in Lebanon, NH | 70 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 1 companies. The companies reported $23,580 in research payments for these studies, mostly to the institutions running them.
- Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease
AbbVie Inc. · Completed · NCT04379050 - M15-737 - Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson Disease
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.